NCT06650423View on ClinicalTrials.gov

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

Not yet recruitingOBSERVATIONAL

Enrollment

319

Participants

Timeline

Start Date

October 20, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

March 1, 2026

Conditions

Early Breast CancerHormone Receptor Positive TumorHER2-negative Breast Cancer

All Listed Sponsors

collaborator

University of Ljubljana

OTHER

lead

Erika Matos

OTHER